Ammar Azzam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ammar Azzam has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Mh Al-Mudhafar
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
1 shared publication - Fadhil Abdulameer Wdaah Alsailawi
COLLEGE OF PHARMACY, UNIVERSITY OF ALTOOSI, NAJAF , IRAQ
1 shared publication - Heider Qassam
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
1 shared publication - Karrar Kareem Gaen
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
1 shared publication - Mohammed Sh. Sachit
College of Pharmacy, Al-Zahrawi University, Karbala, Iraq
1 shared publication - Najah Rayish Hadi
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
1 shared publication
Latest Publications
- 27 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Ameliorative effects of bevacizumab against sepsis-induced acute kidney injury: investigation of inflammatory responses, pyroptosis-related signalling and angiogenesis in a murine model of polymicrobial sepsis
Sepsis is a clinical issue with a major impact on in-hospital patients, resulting in multiple organ damage and increased risk of death. Acute kidney injury (AKI) is the most common organ that is vulnerable to sepsis and may progress to renal failure if not treated. Bevacizumab is a biopharmaceutical agent that disrupts the angiogenesis signalling pathway by binding to vascular endothelial growth factor (VEGF) and preventing it from coupling with cognate receptors. The present study aimed to assess the renoprotective potential of bevacizumab against sepsis-induced renal injury. Four cohorts (6 mice per group) were randomly allocated and included a sham cohort, which was exposed to a midline incision only; the cecal ligation and puncture (CLP) cohort underwent CLP; the vehicle cohort was pretreated with normal saline 1 h prior to the CLP; and the bevacizumab cohort was treated with 0.1 mg/kg bevacizumab 1 h before the CLP. After 24 h, the mice were euthanised, and the blood and kidneys were collected. The results revealed that the levels of urea, creatinine, TNF-α, IL-6, caspase 11, ICAM-1, VEGF and angiopoietin-2 were greater in septic mice than in sham mice. These levels were decreased in septic mice pretreated with bevacizumab. Histological assessment of renal tissues revealed that the kidneys of septic mice were injured, influencing 90% of the renal tubules. Pretreatment with bevacizumab mitigated renal tissue damage. This study demonstrated that bevacizumab has promising renoprotective effects against sepsis-induced renal injury via modulation of inflammatory responses, angiogenesis and pyroptosis-associated signalling.
- 27 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Ameliorative effects of bevacizumab against sepsis-induced acute kidney injury: investigation of inflammatory responses, pyroptosis-related signalling and angiogenesis in a murine model of polymicrobial sepsis
Sepsis is a clinical issue with a major impact on in-hospital patients, resulting in multiple organ damage and increased risk of death. Acute kidney injury (AKI) is the most common organ that is vulnerable to sepsis and may progress to renal failure if not treated. Bevacizumab is a biopharmaceutical agent that disrupts the angiogenesis signalling pathway by binding to vascular endothelial growth factor (VEGF) and preventing it from coupling with cognate receptors. The present study aimed to assess the renoprotective potential of bevacizumab against sepsis-induced renal injury. Four cohorts (6 mice per group) were randomly allocated and included a sham cohort, which was exposed to a midline incision only; the cecal ligation and puncture (CLP) cohort underwent CLP; the vehicle cohort was pretreated with normal saline 1 h prior to the CLP; and the bevacizumab cohort was treated with 0.1 mg/kg bevacizumab 1 h before the CLP. After 24 h, the mice were euthanised, and the blood and kidneys were collected. The results revealed that the levels of urea, creatinine, TNF-α, IL-6, caspase 11, ICAM-1, VEGF and angiopoietin-2 were greater in septic mice than in sham mice. These levels were decreased in septic mice pretreated with bevacizumab. Histological assessment of renal tissues revealed that the kidneys of septic mice were injured, influencing 90% of the renal tubules. Pretreatment with bevacizumab mitigated renal tissue damage. This study demonstrated that bevacizumab has promising renoprotective effects against sepsis-induced renal injury via modulation of inflammatory responses, angiogenesis and pyroptosis-associated signalling.
- 27 February 2026
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 79 (2) , 362-369
Dose Adjustment of Oral Thyroxine in Patients Consuming Dairy Products: A Cohort Retrospective Study
Aim: Aims: Hypothyroidism management with levothyroxine might be affected by a range of factors, including diet. Dairy sources are rich in calcium and proteins which may interfere with the absorption of thyroxine so dose adaptability might be required. This study assesses the effect of dairy intake on levothyroxine dose and clinical outcomes. Material and methods: Methodology: Retrospective cohort study over 14 months in an endocrinology center in Najaf, included 150 adult patients with primary hypothyroidism on stable oral levothyroxine therapy. We classified individuals into high, medium and low dairy consumers. A comparative approach was performed between these groups on terms of the dose, time to stabilization, dose response, clinical outcome, and economic outcome. Results: Results: After multivariable analysis, we found that participants who consumed one or more servings of dairy products per day were 6.8 times more likely to report taking their medications at least once with inadequate preparation p<0.001. These findings suggest that dietary interventions targeting dairy intake could stabilize treatment and reduce healthcare costs. Conclusions: Conclusion: Dietary intake of dairy has a major impact on both the absorption and dosing of levothyroxine in hypothyroid patients. Given the healthcare burden arising from dose adjustments, clinicians should consider dietary counselling and timing strategies to improve therapy.
- 27 February 2026
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 79 (2) , 362-369
Dose Adjustment of Oral Thyroxine in Patients Consuming Dairy Products: A Cohort Retrospective Study
Aim: Aims: Hypothyroidism management with levothyroxine might be affected by a range of factors, including diet. Dairy sources are rich in calcium and proteins which may interfere with the absorption of thyroxine so dose adaptability might be required. This study assesses the effect of dairy intake on levothyroxine dose and clinical outcomes. Material and methods: Methodology: Retrospective cohort study over 14 months in an endocrinology center in Najaf, included 150 adult patients with primary hypothyroidism on stable oral levothyroxine therapy. We classified individuals into high, medium and low dairy consumers. A comparative approach was performed between these groups on terms of the dose, time to stabilization, dose response, clinical outcome, and economic outcome. Results: Results: After multivariable analysis, we found that participants who consumed one or more servings of dairy products per day were 6.8 times more likely to report taking their medications at least once with inadequate preparation p<0.001. These findings suggest that dietary interventions targeting dairy intake could stabilize treatment and reduce healthcare costs. Conclusions: Conclusion: Dietary intake of dairy has a major impact on both the absorption and dosing of levothyroxine in hypothyroid patients. Given the healthcare burden arising from dose adjustments, clinicians should consider dietary counselling and timing strategies to improve therapy.